A Clinical Study of Two Dentinal Hypersensitivity Treatments Used With Normal Oral Hygiene

Sponsor
Procter and Gamble (Industry)
Overall Status
Completed
CT.gov ID
NCT02221349
Collaborator
(none)
30
1
2
2
15

Study Details

Study Description

Brief Summary

This study will compare the safety and effectiveness of normal oral hygiene with two different marketed dentifrices, on longer term dentinal hypersensitivity response following use of potassium oxalate desensitizers.

Condition or Disease Intervention/Treatment Phase
  • Device: Potassium oxalate
  • Drug: Sodium fluoride paste
  • Drug: Stannous fluoride paste
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
30 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
A Randomized Clinical Study of the Safety and Effectiveness of Two Dentinal Hypersensitivity Treatments Used With Normal Oral Hygiene
Study Start Date :
Aug 1, 2014
Actual Primary Completion Date :
Oct 1, 2014
Actual Study Completion Date :
Oct 1, 2014

Arms and Interventions

Arm Intervention/Treatment
Other: oxalate liquid & gel plus SnF2 paste

Potassium oxalate liquid, professionally applied Potassium oxalate gel, self applied Stannous fluoride paste, self applied

Device: Potassium oxalate
Professionally applied (liquid) and self applied (gel)

Drug: Stannous fluoride paste
Toothpaste used by subject
Other Names:
  • SnF2 paste
  • Other: oxalate liquid & gel plus NaF paste

    Potassium oxalate liquid, professionally applied Potassium oxalate gel, self applied Sodium fluoride paste, self applied

    Device: Potassium oxalate
    Professionally applied (liquid) and self applied (gel)

    Drug: Sodium fluoride paste
    Toothpaste used by subject
    Other Names:
  • NaF paste
  • Outcome Measures

    Primary Outcome Measures

    1. Change From Baseline Air Challenge [60 days]

      The Schiff Sensitivity Scale was assessed for each test tooth via an evaporative air challenge. The examiner recorded the Schiff Index score corresponding to the response to the air challenge. The Schiff Index Sensitivity scale is scored as follows: 0: tooth/subject did not respond to stimulus, 1: tooth/subject responds to stimulus, but does not request discontinuation of stimulus, 2: tooth/subjects responds to stimulus and requests discontinuation or moves from stimulus, 3: tooth/subject responds to stimulus considers stimulus to be painful, and requests discontinuation of the stimulus. The higher the Schiff score, the more sensitive the tooth. The mean change from Baseline was calculated for this measure.

    Secondary Outcome Measures

    1. Change From Baseline Visual Analog Scale [60 days]

      Visual Analog Scale (VAS) - subjects are asked to look at a VAS and designate the level of hypersensitivity they experienced as a result of the thermal and water challenges using a continuum scale of 0 = No tooth pain up to 100 = Worst tooth pain ever experienced.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Be at least 18 years of age

    • Provide written informed consent prior to participation and be given a signed copy of the informed consent form

    • Complete a confidentiality disclosure agreement

    • Be in good general health as determined by the Investigator/designee

    • Have at least one tooth with a Schiff sensitivity score of at least 1 in response to the air challenge.

    Exclusion Criteria:
    • Self-reported pregnancy or nursing

    • Severe periodontal disease, as characterized by purulent exudate, generalized mobility, and/or severe recession

    • Active treatment of periodontitis

    • Fixed facial orthodontic appliances

    • A history of kidney stones

    • Known allergies to the following ingredients; aqua, glycerin, cellulose gum, dipotassium oxalate, carbomer, sodium hydroxide, sodium benzoate, and potassium sorbate

    • Any diseases or conditions that might interfere with the safe completion of the study

    • An inability to undergo any study procedures.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Chad J Anderson DMD Inc Fresno California United States 93730

    Sponsors and Collaborators

    • Procter and Gamble

    Investigators

    • Principal Investigator: Chad J Anderson, MS, DMD, Chad J Anderson DMD Inc

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Procter and Gamble
    ClinicalTrials.gov Identifier:
    NCT02221349
    Other Study ID Numbers:
    • 2014069
    First Posted:
    Aug 20, 2014
    Last Update Posted:
    Sep 9, 2020
    Last Verified:
    Sep 1, 2020
    Keywords provided by Procter and Gamble
    Additional relevant MeSH terms:

    Study Results

    Participant Flow

    Recruitment Details
    Pre-assignment Detail
    Arm/Group Title Oxalate Liquid & Gel Plus SnF2 Paste Oxalate Liquid & Gel Plus NaF Paste
    Arm/Group Description Potassium oxalate liquid, professionally applied Potassium oxalate gel, self applied Stannous fluoride paste, self applied Potassium oxalate: Professionally applied (liquid) and self applied (gel) Stannous fluoride paste: Toothpaste used by subject Potassium oxalate liquid, professionally applied Potassium oxalate gel, self applied Sodium fluoride paste, self applied Potassium oxalate: Professionally applied (liquid) and self applied (gel) Sodium fluoride paste: Toothpaste used by subject
    Period Title: Overall Study
    STARTED 15 15
    COMPLETED 14 15
    NOT COMPLETED 1 0

    Baseline Characteristics

    Arm/Group Title Oxalate Liquid & Gel Plus SnF2 Paste Oxalate Liquid & Gel Plus NaF Paste Total
    Arm/Group Description Potassium oxalate liquid, professionally applied Potassium oxalate gel, self applied Stannous fluoride paste, self applied Potassium oxalate: Professionally applied (liquid) and self applied (gel) Stannous fluoride paste: Toothpaste used by subject Potassium oxalate liquid, professionally applied Potassium oxalate gel, self applied Sodium fluoride paste, self applied Potassium oxalate: Professionally applied (liquid) and self applied (gel) Sodium fluoride paste: Toothpaste used by subject Total of all reporting groups
    Overall Participants 15 15 30
    Age (Count of Participants)
    <=18 years
    0
    0%
    0
    0%
    0
    0%
    Between 18 and 65 years
    15
    100%
    15
    100%
    30
    100%
    >=65 years
    0
    0%
    0
    0%
    0
    0%
    Age (years) [Mean (Standard Deviation) ]
    Mean (Standard Deviation) [years]
    41.5
    (10.97)
    44.9
    (12.52)
    43.2
    (11.69)
    Sex: Female, Male (Count of Participants)
    Female
    14
    93.3%
    14
    93.3%
    28
    93.3%
    Male
    1
    6.7%
    1
    6.7%
    2
    6.7%
    Race/Ethnicity, Customized (Count of Participants)
    Hispanic
    1
    6.7%
    2
    13.3%
    3
    10%
    American Indian
    0
    0%
    1
    6.7%
    1
    3.3%
    Asian Oriental
    2
    13.3%
    0
    0%
    2
    6.7%
    Black
    2
    13.3%
    0
    0%
    2
    6.7%
    Caucasian
    10
    66.7%
    11
    73.3%
    21
    70%
    Multi-Racial
    0
    0%
    1
    6.7%
    1
    3.3%

    Outcome Measures

    1. Primary Outcome
    Title Change From Baseline Air Challenge
    Description The Schiff Sensitivity Scale was assessed for each test tooth via an evaporative air challenge. The examiner recorded the Schiff Index score corresponding to the response to the air challenge. The Schiff Index Sensitivity scale is scored as follows: 0: tooth/subject did not respond to stimulus, 1: tooth/subject responds to stimulus, but does not request discontinuation of stimulus, 2: tooth/subjects responds to stimulus and requests discontinuation or moves from stimulus, 3: tooth/subject responds to stimulus considers stimulus to be painful, and requests discontinuation of the stimulus. The higher the Schiff score, the more sensitive the tooth. The mean change from Baseline was calculated for this measure.
    Time Frame 60 days

    Outcome Measure Data

    Analysis Population Description
    Thirty (30) subjects received study products and were measured at the Baseline visit. Twenty-Nine (29) subjects completed the study thus, one subject dropped from the study prior to Day 60 and was not analyzed for the 60 day measure.
    Arm/Group Title Oxalate Liquid & Gel Plus SnF2 Paste Oxalate Liquid & Gel Plus NaF Paste
    Arm/Group Description Potassium oxalate liquid, professionally applied Potassium oxalate gel, self applied Stannous fluoride paste, self applied Potassium oxalate: Professionally applied (liquid) and self applied (gel) Stannous fluoride paste: Toothpaste used by subject Potassium oxalate liquid, professionally applied Potassium oxalate gel, self applied Sodium fluoride paste, self applied Potassium oxalate: Professionally applied (liquid) and self applied (gel) Sodium fluoride paste: Toothpaste used by subject
    Measure Participants 14 15
    Mean (Standard Deviation) [Units on a scale]
    -1.643
    (0.770)
    -1.500
    (0.906)
    2. Secondary Outcome
    Title Change From Baseline Visual Analog Scale
    Description Visual Analog Scale (VAS) - subjects are asked to look at a VAS and designate the level of hypersensitivity they experienced as a result of the thermal and water challenges using a continuum scale of 0 = No tooth pain up to 100 = Worst tooth pain ever experienced.
    Time Frame 60 days

    Outcome Measure Data

    Analysis Population Description
    Thirty (30) subjects received study products. Twenty-Nine (29) subjects completed the study thus, one subject dropped from the study prior to Day 60 and was not analyzed for the 60 day measure.
    Arm/Group Title Oxalate Liquid & Gel Plus SnF2 Paste Oxalate Liquid & Gel Plus NaF Paste
    Arm/Group Description Potassium oxalate liquid, professionally applied Potassium oxalate gel, self applied Stannous fluoride paste, self applied Potassium oxalate: Professionally applied (liquid) and self applied (gel) Stannous fluoride paste: Toothpaste used by subject Potassium oxalate liquid, professionally applied Potassium oxalate gel, self applied Sodium fluoride paste, self applied Potassium oxalate: Professionally applied (liquid) and self applied (gel) Sodium fluoride paste: Toothpaste used by subject
    Measure Participants 14 15
    Mean (Standard Deviation) [Units on a scale]
    -29.82
    (18.65)
    -24.67
    (26.75)

    Adverse Events

    Time Frame
    Adverse Event Reporting Description
    Arm/Group Title Oxalate Liquid & Gel Plus SnF2 Paste Oxalate Liquid & Gel Plus NaF Paste
    Arm/Group Description Potassium oxalate liquid, professionally applied Potassium oxalate gel, self applied Stannous fluoride paste, self applied Potassium oxalate: Professionally applied (liquid) and self applied (gel) Stannous fluoride paste: Toothpaste used by subject Potassium oxalate liquid, professionally applied Potassium oxalate gel, self applied Sodium fluoride paste, self applied Potassium oxalate: Professionally applied (liquid) and self applied (gel) Sodium fluoride paste: Toothpaste used by subject
    All Cause Mortality
    Oxalate Liquid & Gel Plus SnF2 Paste Oxalate Liquid & Gel Plus NaF Paste
    Affected / at Risk (%) # Events Affected / at Risk (%) # Events
    Total 1/14 (7.1%) 0/15 (0%)
    Serious Adverse Events
    Oxalate Liquid & Gel Plus SnF2 Paste Oxalate Liquid & Gel Plus NaF Paste
    Affected / at Risk (%) # Events Affected / at Risk (%) # Events
    Total 0/14 (0%) 0/15 (0%)
    Other (Not Including Serious) Adverse Events
    Oxalate Liquid & Gel Plus SnF2 Paste Oxalate Liquid & Gel Plus NaF Paste
    Affected / at Risk (%) # Events Affected / at Risk (%) # Events
    Total 1/14 (7.1%) 0/15 (0%)
    Gastrointestinal disorders
    Hyperesthesia 1/14 (7.1%) 2 0/15 (0%) 0
    PAIN 1/14 (7.1%) 1 0/15 (0%) 0

    Limitations/Caveats

    [Not Specified]

    More Information

    Certain Agreements

    All Principal Investigators ARE employed by the organization sponsoring the study.

    There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

    Results Point of Contact

    Name/Title Clinical Trial Manager
    Organization The Procter & Gamble Company
    Phone 513-622-2489
    Email peters.j.2@pg.com
    Responsible Party:
    Procter and Gamble
    ClinicalTrials.gov Identifier:
    NCT02221349
    Other Study ID Numbers:
    • 2014069
    First Posted:
    Aug 20, 2014
    Last Update Posted:
    Sep 9, 2020
    Last Verified:
    Sep 1, 2020